Ikeda, Japan

Kiyotaka Ito

This inventor holds 13 USPTO granted patents. Top assignee: Fujisawa Pharmaceutical Company, Ltd.. Active years: 1986-2004.


% Patents Active = 92.3

Average Co-Inventor Count = 3.4

ph-index = 5

Forward Citations = 111(Granted Patents)


Location History:

  • Ibaragi, JP (1986 - 1989)
  • Ikeda, JP (1989 - 1994)
  • Osaka, JP (1992 - 2004)

Company Filing History:


Years Active: 1986-2004

Loading Chart...
13 patents (USPTO):Explore Patents

Title: Kiyotaka Ito: Innovator in Therapeutic Agents

Introduction

Kiyotaka Ito is a prominent inventor based in Ikeda, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of therapeutic agents for ischemic diseases. With a total of 13 patents to his name, Ito's work has had a considerable impact on medical science.

Latest Patents

One of Kiyotaka Ito's latest patents involves amide compounds that serve as therapeutic agents for ischemic diseases. This invention relates to a method of treating cardiac ischemic disease using a specific compound formula. The innovative approach aims to provide effective treatment options for patients suffering from this condition.

Career Highlights

Kiyotaka Ito is associated with Fujisawa Pharmaceutical Company, Ltd., where he has been instrumental in advancing research and development in the pharmaceutical sector. His expertise and dedication have led to numerous breakthroughs in therapeutic applications.

Collaborations

Throughout his career, Kiyotaka Ito has collaborated with notable colleagues, including Hisashi Takasugi and Takao Takaya. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Kiyotaka Ito's contributions to the field of pharmaceuticals, particularly in the area of ischemic disease treatment, highlight his role as a leading inventor. His ongoing work continues to inspire advancements in medical science and improve patient outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…